Idacta mAb INT-001 represents an interesting clinical approach for combating certain blood-related malignancies. The immunoglobulin is the special mechanism of action, particularly targeting CD38, an cell-surface https://inesppql887626.wikiannouncement.com/10380303/idacta_mab_int_001_the_novel_immunoglobulin_in_progression